Thursday, February 09, 2012

Site Search

Archive for the ‘Medicinal Chemistry’ Category

Nigeria: FG and Cost of Cancer Screening

THE Federal Government’s recent directive to its hospitals to reduce the cost of cancer screening, though very commendable, is long overdue, considering that late diagnosis of the disease has resulted in the high rate of cancer related deaths in the country.

Cancer is one of the leading causes of deaths in the world, especially in developing countries, which carry about 80 per cent of the burden, globally. Unfortunately, in Nigeria with over 160 million people, going by the latest global report on population, detection of the killer non-communicable disease (NCD) is usually late.

Minister of Health, Prof. Onyebuchi Chukwu, who announced the reduction in the cost of screening for breast, cervical, prostate and colon cancers during the recent 17th Annual Conference of the Nigerian Association of Urological Surgeons (NAUS) in Abuja, said the directive to provide screening services at affordable prices is to ensure that the disease is detected early.

Other measures being taken by government to tackle the cancer scourge, he said, include equipping fully the University of Port Harcourt Teaching Hospital, the Federal Medical Centre, Gusau, Zamfara State and the Vesico Virginal Fistula (VVF) Centre, Abakaliki, Ebonyi State with mammography machines, cryoprobes, video culposcopes, ultrasound, loop electrosurgical excision procedure and enzyme-linked immunosorbent assay machines, so that these institutions can serve as referral centres for those who screen positive for pre-malignant lesions.

With the World Health Organisation (WHO) projecting that about 84 million people may die of cancer by 2015 if urgent steps are not taken to arrest the scourge, there is, indeed, need to facilitate a national policy on cancer management, starting with free or significantly reduced cost of cancer screening.

These moves by the Federal Government are steps in the right direction, considering that cancer is one disease that is no respecter of social status and one that has continued to deal devastating blows on the productive segments of the nation’s economy.

Among notable Nigerians whose lives were cut short by cancer are human rights activist and lawyer, Chief Gani Fawehinmi, who died in 2009 after a prolonged battle with lung cancer, Dr. Bekolari Ransome-Kuti, a medical doctor and human rights activist and Yemi Tella, coach of the Nigerian 2007 FIFA U-17 World Cup winning team.

Maryam, wife of former military president, Gen. Ibrahim Babangida, died of ovarian cancer on December 27, 2009 at California’s City Hope Hospital in the United States, aged 61, while the wife of Edo State Governor, Adams Oshiomhole, was swept away by cancer of the breast.

Presently, about two million cancer cases are said to be recorded in Nigeria with an estimated 350,000 new cases being diagnosed annually. Of the two million, only 10 per cent or about 200,000, have access to hospitals with radiotherapy facilities, while out of the number, only five per cent, about 10,000, have the resources to go abroad where they pay between $10,000 and $15,000 per patient for a three to five-weeks course of radiotherapy.

While about 27 per cent of the two million cases are suffering from breast cancer, about 25 per cent are cancer of the cervix cases. And of these two cancers that are devastating women in Nigeria, one has good prognosis, if detected early, while the other can be prevented. Yet they continue to cause untold hardships and deaths simply because of the dearth, and high cost, of facilities, especially for early detection, among other constraints.

Nigeria’s mortality and morbidity statistics for cancer are said to be high due to the late presentation syndrome involving 83-87 per cent of cancer patients, simply because the awareness level of Nigerians, especially women, is very low, even as this is dogged by superstition and cultural restraints.

As a matter of fact, some medical experts have argued that even the estimated 350,000 new cases of cancer diagnosed annually in Nigeria is far from the true figure of the cancer crisis in the country, insisting that a large number of cancers are not detected as majority of Nigerians are poor and live in rural areas, far removed from health facilities.

Lack of, or inadequate, research into this debilitating disease is also a major challenge. Nigeria, for instance, is said to contribute little or nothing to the global body of literature on cancers and most of these contributions are hospital based, perhaps representing the tip of the iceberg as majority of Nigerians live in rural areas, unable to access any health facilities.

As such, the cancer awareness efforts and screening methods to enhance early detection do not seem to have had much impact on the nation.

No doubt, the problems of lack of access to quality health care, ignorance, poverty and poor co-ordination of issues of health education complicate issues. For instance, facilities such as computerised tomography (CT) and Magnetic Resonance Imaging (MRI) are difficult to come by, and when available, the cost of accessing such facilities put them out of reach of the average citizen.

Of more concern is the fact that clinical services for cancer are grossly inadequate and poorly distributed. Only a few centers have functioning radiotherapy equipment, and though radiologic services are said to be generally available, access is seriously limited by high cost.

So, while the Federal Government’s move to reduce the cost of cancer screening in federal hospitals is commended, we call on the authorities to ensure that the screening equipment are available and more easily accessible, especially in the rural areas, while a more vigorous and better co-ordinated effort into cancer research must be encouraged in institutions across the country.

Source: http://allafrica.com/stories/201111241060.html

Vaccine for ovarian, breast cancer shows promise

(CBS) A new vaccine that targets ovarian and breast cancer has shown promise in early studies, giving scientists hope they may be closer to stopping the deadly diseases.

PICTURES: 25 breast cancer myths busted

Known as PANVAC, the vaccine triggers the immune system to attack tumor cells.

“With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients,” lead scientist Dr. James Gulley, director and deputy chief of the clinical trials group at the laboratory of tumor immunology and biology at the National Cancer Institute, said in a written statement.

For their research, published in the Nov. 8 issue of Clinical Cancer Research, scientists tested the vaccine on 26 patients, 12 of whom had breast cancer, 14 of whom ovarian. Most of the women had undergone prior chemotherapy treatment.

What did the scientists find? The vaccine caused women with breast cancer’s disease progression to stall for 2.5 months, and their median survival was 14 months. Four had stable disease, meaning the cancer didn’t grow nor shrink. Women with ovarian cancer reported a two month gap in disease progression, and survived for 15 months, and three had stable disease.

The cancer vaccine stalls cancer progression for only a couple of months? What’s the big deal?

“That time frame is not anything to write home about,” Gulley told WebMD. But he said that one of the women who had breast cancer currently shows evidence of cancer after undergoing the experimental vaccine – four years later.

“It gives us encouragement that we may be on to something here,” he said.

That 32-year-old woman was the youngest in the study, according to WebMD, but her cancer had spread to her liver and chest lymphnodes. At 18 months, there was no X-ray evidence of cancer. Gulley isn’t sure why her treatment was so successful, but the woman had only undergone chemotherapy once. That suggests her immune system might have been stronger than the other women’s.

But don’t expect the vaccine on the market anytime soon. This was only a small study, so more needs to be done.

Gulley said interest in a cancer vaccine is increasing among scientists, but said in the statement that “more studies in the appropriate patient populations are required” to ensure safety, and which patients would benefit most.

The National Cancer Institute has more on cancer vaccines in development.

Source: http://www.cbsnews.com/8301-504763_162-57321522-10391704/vaccine-for-ovarian-breast-cancer-shows-promise/

X-Body BioSciences and Tanabe Research Labs Team Up to Develop mAbs for Autoimmune Diseases

X-Body Biosciences entered a partnership with Tanabe Research Laboratories (TRL) to identify therapeutic target epitopes and develop monospecific and/or bispecific antibodies against those targets. TRL is focussed on discovery and development of biologicals for autoimmune diseases.

Under terms of the deal, X-Body will be responsible for screening, and TRL will fund the work. TRL has the option to negotiate rights to the antibodies discovered in the collaboration for further preclinical research, clinical development, and commercialization.

X-Body will leverage its human antibody library and Protein Chain Reaction™ screening technology. The platform reportedly allows for screening against cell surface targets in their native state on live cells or purified target proteins.

This selection system employs next-generation sequencing to analyze thousands of hits to obtain high-quality leads. The modular leads generated can be incorporated into V(H) domain, scFv, IgG, and bispecific antibody formats.

“X-Body’s technology represents a major step forward in the ability to rapidly generate thousands of human antibodies against functionally relevant targets,” according to Roland Newman, Ph.D., CSO of TRL. “The power and versatility of X-Body’s platform in generating antibodies against targets that are inaccessible by conventional techniques offers new and exciting prospects.”

Source: http://www.genengnews.com/gen-news-highlights/x-body-biosciences-and-tanabe-research-labs-team-up-to-develop-mabs-for-autoimmune-diseases/81245774/

Body & Mind – HEALTH U.S. Doctor Cautious About HIV Vaccine

A New York City-based infectious disease specialist said a new vaccine developed by Spanish scientists, which could turn HIV into minor infection status, is reason to be cautiously optimistic.

Dr. Joseph Rahimian said Thursday news of an HIV vaccine is certainly exciting, but questions remain.

“An HIV vaccine has been the holy grail for infectious disease doctors for a very long time,” Rahimian said. “ There are a lot of people interested in creating one and obviously a lot of demand for it, so there would be a lot of excitement if this research is accurate.”

The vaccine, developed by scientists at the Spanish Superior Scientific Research Council (CSIC) in Madrid, works by training the immune system to detect HIV and learn how to combat the virus.

In a trial involving 30 healthy volunteers, scientists found that 90 percent of those who were given the MVA-B vaccine developed an immunity against the virus and 85 percent maintained this for a year.

Professor Mariano Esteban, from CSIC, said, “MVA-B vaccine has proven to be as powerful as any other vaccine currently being studied, or even more.”

He said the vaccine was like showing the body a picture of the HIV, “so that it is able to recognize it if it sees it again in the future.”

“If the virus enters the body and tries to develop in a cell, the immune system is ready to inactivate the virus and destroy the infected cell,” he added. Scientists hope that if bigger trials are successful, HIV would no longer cause AIDS and would be much less contagious.

‘”If this genetic cocktail passes Phase II and Phase III future clinic trials, and makes it into production, in the future HIV could be compared to herpes virus nowadays,” according to the study.

However, Rahimian said this study needs much more room to grow.

“The population that they used is very small, and they followed them out to one year. So one important question is how long does this last for? A vaccine that has to be given repeatedly every year is less exciting than a vaccine that can give long-term immunity,” he said.

On the other hand, Rahimian pointed out there are some vaccines given every year, which are successful, like the flu shot.

“I would say many people have tried to create vaccines, and it is a very difficult task, so any enthusiasm for a successful vaccine is guarded,” he said.

Source: http://www.foxnews.com/health/2011/09/29/new-vaccine-could-turn-hiv-into-minor-infection/

Canadian-made virus shows promise as cancer treatment

An Ottawa-based research team has developed a virus that is showing promise as a new way of attacking and shrinking cancer tumours while leaving healthy tissue alone.

It’s early days in the still-experimental field of therapeutic cancer viruses, called oncolytic viruses. But this new study from researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa advances the field a little further by showing that the virus is safe in most patients.

For the study, researchers recruited 23 advanced cancer patients whose cancer had spread to multiple organs. All had failed to respond to the usual treatments and all were in the final stages of the disease.

The patients agreed to receive a single infusion of an experimental virus into their blood, called JX-594.

JX-594 is a form of vaccinia virus that’s been used as a live vaccine against smallpox. The JX-594 virus has been genetically engineered to enhance its natural anti-cancer properties.

The doctors tried out five doses of the virus, and then took biopsies of the tumours eight to 10 days later.

The researchers found that seven of the eight patients in the highest dose groups had evidence that the virus was in place and replicating in their tumours — and not in normal tissues.

What’s more, six of eight patients in the two highest dose groups experienced a shrinking or stabilization of their tumours, while those in lower dose groups saw less of this effect.

None of the 23 patients experienced significant side effects from the virus injection, with the most common side effect being mild to moderate flu-like symptoms that lasted less than one day.

The study, which is published in the journal Nature, was designed primarily to test the safety of the virus, not to cure the patients. In fact, some of the patients later died of their disease.

But the observation that some patients saw their tumours shrink was a welcome discovery.

Dr. John Bell, one of the study’s co-authors and a researcher at OHRI says it’s exciting that the virus led to results after just one dose.

“Of course, we will need to do more trials to know if this virus can truly make a difference for patients,” he said in a statement.

Bell says the advantage of therapeutic viruses is that they can be sent through the blood, infect the cancer tumours and leave the healthy tissue alone. It’s possible that oncolytic viruses could one day offer an alternative to conventional chemotherapy and radiation treatment, which tend to destroy healthy cells as well as cancer cells.

“Oncolytic viruses are unique because they can attack tumours in multiple ways, they have very mild side effects compared to other treatments, and they can be easily customized for different kinds of cancer,” Bell said.

“We’re still in the early stages of testing these viruses in patients, but I believe that someday, viruses and other biological therapies could truly transform our approach for treating cancer.”

JX-594 was developed with Jennerex Inc., a biotherapeutics company co-founded by Dr. Bell in Ottawa and Dr. David Kirn in San Francisco.

The study was funded in part by Jennerex, as well as the Terry Fox Foundation, the Canadian Institutes of Health Research and the Ontario Institute for Cancer Research, and others.

Bell and his research team plan to do further tests on many more patients to show the treatment actually works and that the body doesn’t learn to resist the virus over time.

A Phase 2 trial is to start soon aimed at patients with end-stage liver cancer or colon cancer.

Dr. Don Morris, a professor of Medicine and Oncology at the University of Calgary says even if this treatment is shown to be effective in cancer patients, it would be years before it would be widely available.

“Truly, this is not a treatment that could be applied to community cancer patients out of a trial. We may be three, five or seven years away before this is mainstream. The caution is that this is new hope, but tempered hope,” he told CTV News.

Source: http://calgary.ctv.ca/servlet/an/local/CTVNews/20110831/cancer-tumour-virus-ottawa-110831/20110831/?hub=CalgaryHome

Five Genes May Be Tied to Lethal Prostate Cancer

TUESDAY, Aug. 16 (HealthDay News) — In what may be a diagnostic advance, U.S. and Swedish researchers have linked five inherited genetic mutations to the development of a particularly aggressive and deadly form of prostate cancer.

Click here to find out more!

The findings could someday lead to development of an easy-to-administer blood test to screen for such mutations to help physicians assess the long-term risk faced by newly diagnosed prostate cancer patients, the researchers suggested.

“The ability to distinguish patients at elevated risk for having aggressive, life-threatening prostate cancer at the time of diagnosis could improve care for the subset of cases most likely to benefit from aggressive therapy and help avoid over-treatment of patients whose tumors are likely to remain indolent,” the study team, led by Janet L. Stanford, co-director of the Fred Hutchinson Cancer Research Center’s program in prostate cancer research, reported in the Aug. 16 online edition of Cancer Epidemiology, Biomarkers and Prevention.

At issue are longstanding concerns about unnecessary over-treatment of many prostate cancer patients who actually face a relatively low risk for fast disease progression and death. Because treatment can bring about undesirable side effects, such as sexual impotence and urinary incontinence, an effort has been under way to achieve a more personalized assessment of a patient’s particular prognosis after diagnosis.

“Biomarkers that could distinguish between patients with indolent vs. more aggressive tumors are urgently needed,” Stanford said in a journal news release. “The panel of markers we’ve identified provides the first validated evidence that inherited genetic variants play a role in prostate cancer progression and mortality. Ultimately these markers could be used in the clinic, along with other known predictors that are used to assess tumor aggressiveness, such as a high Gleason score, to identify men with a high-risk profile.”

The authors, looking for genetic differences that could highlight risk differences, gathered blood samples from more than 1,300 prostate cancer patients living in the Seattle region. All were between the ages of 35 and 74 when diagnosed.

DNA analyses of the samples were compiled with those of nearly 2,900 Swedish prostate cancer patients.

The result: Five single-letter mutations (or SNPs) were isolated among the patients’ “DNA alphabet” as having a significant bearing on prostate cancer progression in terms of affecting cell death, tumor growth, inflammation, androgen hormone levels, blood-vessel development and bone density.

Patients found to have at least four out of the five cited SNP mutations appeared to face a 50 percent higher risk for dying from their disease compared with those who carried two or fewer of the mutations.

William Phelps, program director of translational and preclinical cancer research at the American Cancer Society, said the push to develop more revealing diagnostic tools is driven by an acknowledgement that current treatment options can debilitate patients.

“If the treatments we had for prostate cancer were very tolerable or very safe you would probably treat everybody,” he explained. “But the treatments we have available today are less than ideal.”

“So certainly we can try to improve treatment,” Phelps noted. “But at the same time we can also try to improve ways to identify patients who are more likely to progress rapidly from those likely to be very slow going, so we can reserve treatment for only those instances when it’s really necessary.”

If there are markers that better define the men whose cancer is most likely to progress, “that would certainly prove very useful in the current climate,” he said.

Source: http://health.usnews.com/health-news/family-health/cancer/articles/2011/08/16/five-genes-may-be-tied-to-lethal-prostate-cancer

Suicide-Bombing Bacteria Could Fight Infections

Like any good military unit, infectious bacteria have access to numerous weapons and efficient communication systems. But like soldiers in the field, they’re also susceptible to suicide bombers. Researchers have used the tools of synthetic biology to create an Escherichia coli cell that can infiltrate foreign bacteria and explode, killing off the pathogens along with itself.

The project, says bioengineer Chueh Loo Poh of Nanyang Technological University in Singapore, was “inspired by nature,” particularly by quorum sensing, the ability of some bacteria to detect the number of microorganisms—either of their own species or others—in their environment. When pathogenic Pseudomonas aeruginosa sense other species impeding on their space and nutrients, they communicate with members of their own species using chemical signals and collectively start releasing a bacterial toxin called pyocin that kills off the competition. Together, these communication and defense capabilities allow P. aeruginosa to form tightly packed layers called biofilms, which can cause respiratory tract infections in humans and are particularly dangerous to cystic fibrosis patients.

Poh and chemical engineer Matthew Wook Chang, also at Nanyang Technological University, decided to turn P. aeruginosa‘s weapon system against itself, using E. coli as the carrier. The researchers tweaked the genes that allow P. aeruginosa to detect other members of its species and put this synthetic genetic code into E. coli‘s genome. They also gave E. coli a gene for making a modified pyocin that is toxic to P. aeruginosa. By linking the pyocin gene to the sensing genes, the researchers ensured that when the E. coli detected P. aeruginosa in the vicinity, it would fill itself with large amounts of pyocin and become a biological time bomb.

The researchers gave E. coli one last synthetic component: a “suicide gene” that is activated once the pyocin has had some time to build up, causing the cells to burst open and release their toxin. When Chang and Poh grew these synthetic E. coli in a dish with P. aeruginosa, the suicide bomber was able to kill 99% of the P. aeruginosa cells, the researchers report today in Molecular Systems Biology.

Justin Gallivan, a synthetic biologist at Emory University in Atlanta, says in an e-mail that the study “nicely illustrates” how synthetic bacteria can perform complex tasks. But he worries they may not be able to finish the job, because 1% of the infectious bacteria remained after the treatment—even when the researchers put four times as many E. coli as P. aeruginosa into the mix.

The system would also have to undergo a lot of work before it can be considered for use in humans—including, perhaps, replacing E. coli with another delivery system, says Richard Kitney, a synthetic biologist at Imperial College London. “Exposing people to E. coli is not a good thing,” Kitney says, as the bacteria are toxic outside the gut. He adds that the team would also have to show that pyocin is effective at killing P. aeruginosa that have already formed a biofilm.

For their part, Chang and Poh say that they plan to test the suicidal bacteria in mice infected with P. aeruginosa. It’s not clear, they say, whether pyocin is harmful to mammals, although some other natural bacterial toxins are currently approved for use as food preservatives. They also hope to tweak the synthetic system so that it can sense and respond to signaling molecules released by other species of pathogenic bacteria, such as those responsible for cholera.

Source: http://news.sciencemag.org/sciencenow/2011/08/suicide-bombing-bacteria-could-f.html

Urine Test May Help Detect, Stratify Prostate Cancer

In men with elevated prostate specific antigen (PSA), an investigational urine test can detect and stratify prostate cancer, researchers reported.

The test is based on the detection of a gene fusion that is specific to prostate cancer, combined with another marker, according to Arul Chinnaiyan, MD, PhD, of the University of Michigan Medical School in Ann Arbor, and colleagues.

Stratifying patients by the combined marker identified groups with markedly different risks of cancer, high-grade cancer, and clinically significant cancer on biopsy, Chinnaiyan and colleagues reported online in Science Translational Medicine.

The noninvasive test could allow some men with elevated PSA to avoid a needle biopsy, the researchers noted.

“Many more men have elevated PSA than actually have cancer but it can be difficult to determine this without biopsy,” Chinnaiyan said in a statement. “The hope is that this test could be an intermediate step before getting a biopsy.”

The fusion at the heart of the test involves the genes transmembrane protease, serine 2 (TMPRSS2), and v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG).

The fusion appears in about half of all prostate cancers, Chinnaiyan and colleagues noted, but when it appears it is almost 100% specific for malignancy.

In a series of experiments, the researchers showed that the fusion gene was associated with indicators of clinically significant cancer at biopsy and prostatectomy.

The indicators included tumor size, high Gleason score at prostatectomy, and upgrading of Gleason grade at prostatectomy, they reported.

But because the fusion gene is not universally present, the researchers created a model that combined it and the prostate cancer antigen 3 (PCA3) gene.

In 1,065 men who underwent biopsy, the researchers used the model to stratify men into three groups – lowest, intermediate, and highest levels of the combined genes.

They found that the groups had distinctly different patterns of risk. Specifically:

  • 363, 346, and 356 men were in the lowest, intermediate, and highest score groups, respectively – or 34%, 32% and 33%.
  • Biopsy resulted in a cancer diagnosis in 21%, 43%, and 69% of men in the lowest, intermediate, and highest groups, respectively. The difference between the low and high groups was significant at P<0.001.
  • 7%, 20%, and 40% of men in the lowest, intermediate, and highest groups were diagnosed with cancer that had a Gleason score of greater than 6. The difference between the low and high groups was again significant at P<0.001.
  • Of the 966 men with enough information to determine the Epstein criteria for significance of cancer on biopsy, 15%, 33%, and 61% of men in the three groups, respectively, had Epstein-criteria-defined significant cancer.

The researchers cautioned that the test remains investigational. As well, they noted, most of the men studied so far have been Caucasian, so that additional study is needed to see if the results apply more broadly.

Source: http://www.medpagetoday.com/HematologyOncology/ProstateCancer/27884?pfc=101&spc=224

Sanofi Pasteur to Evaluate Leukocare’s Stabilization Technology for Vaccines

    Sanofi Pasteur and Leukocare biotechnology inked a cooperation agreement through which Sanofi’s vaccines division will evaluate Leukocare’s Stabilizing and Protecting Solutions (SPS) platform for improving the shelf-life of certain vaccine formulations.

    Leukocare’s postcoating technology is designed to both stabilize biotherapeutic and diagnostic products and protect them against the otherwise damaging effects of terminal sterilization by irradiation or ethylene oxide. The firm says the platform can be used to help preserve the activity of biologics during processing for dry storage, and is applicable to lyophilization, air drying, spray drying or microcrystal powders.

    Leukocare specializes in technologies for biological functionalization of surfaces and for product stabilization. The firm offers collaborative research and development services that exploit its core technologies in the fields of biofunctional surface engineering, biopharmaceuticals, development and co-development of combination products, as well as related preclinical and clinical studies.

    The SPS technology has been tailored to specific product types. SPS-CP is designed for stabilizing and protecting combination products. SPS-BP is adapted specifically for the stabilization and protection of biopharmaceutical formulations and galenics. SPS-LT is designed to stabilize and protect diagnostic surface coating.

    In November 2010 Leukocare teamed up with sterilization services firm Sterigenics, for a collaboration that aims to combine the SPS platform with Sterigenics irradiation technologies and establish new sterilization procedures for biotherapeutics, including therapeutic antibodies.

    Source: http://genengnews.com/gen-news-highlights/sanofi-pasteur-to-evaluate-leukocare-s-stabilization-technology-for-vaccines/81245462/

Positive agreement received for approval of AXANUM (low-dose ASA/esomeprazole) in Europe

AstraZeneca today announced that AXANUM, a fixed dose combination of 81 mg low-dose ASA (acetylsalicylic acid) and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union member countries and in Norway. AXANUM is indicated for prevention of cardiovascular (CV) events such as heart attack or stroke, in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.

Low-dose ASA (commonly known as aspirin) is recommended mainstay therapy for patients with high-risk for cardiovascular events. About one third of these patients are also at increased risk of stomach ulcer. Low-dose ASA further increases the risk for gastric ulcers and gastrointestinal bleeding. In fact, the most common reason for stopping low-dose ASA treatment is upper gastrointestinal problems. The consequences of interrupting low-dose ASA treatment can be severe, increasing the risk of a heart attack or stroke as early as eight to 10 days later.

AXANUM is the only medicine that ensures every single pill of low-dose ASA comes with built-in protection against gastric ulcers. That means AXANUM has the potential to provide continuous CV protection in this patient population.

The EU decision took place under the decentralised procedure (DCP), with Germany acting as reference member state. This process is now followed by national approvals and local pricing and reimbursement discussions.

Tony Zook, Executive Vice President of AstraZeneca’s Global Commercial Organisation said: “AstraZeneca has had some significant regulatory approvals this year, and we’re pleased with this positive agreement for AXANUM in Europe. We will now work with relevant health authorities to secure reimbursement decisions and get onto formularies to bring this medicine to patients as soon as possible.”

Source: http://www.europeanpharmaceuticalreview.com/8417/news/industry-news/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/?utm_medium=email&utm_campaign=EPR+-+Newsletter+16+2011&utm_content=EPR+-+Newsletter+16+2011+CID_0d42f174df14efdb3a6804bfbf1f416a&utm_source=Email+marketing&utm_term=Positive+agreement+received+for+approval+of+AXANUM+low-dose+ASAesomeprazole+in+Europe

Women who eat lots of fiber have less breast cancer

(Reuters Health) – A fresh look at the medical evidence shows women who eat more fiber are less likely to get breast cancer.

Chinese researchers found those who ate the most of the healthy plant components were 11 percent less likely to develop breast cancer than women who ate the least.

Their findings don’t prove fiber itself lowers cancer risk, however, because women who consume a lot of it might be healthier overall than those who don’t.

The results “can identify associations but cannot tell us what will happen if people change their behavior,” said John Pierce, a cancer research at the University of California, San Diego, who was not involved in the work.

While earlier research has yielded mixed conclusions on the link between cancer and fiber, it would make scientific sense: According to the Chinese researchers, people who eat high-fiber diets have lower levels of estrogen, which is a risk factor for breast tumors.

So to get more clarity, the researchers combined 10 earlier studies that looked at women’s diets and followed them over seven to 18 years to see who developed cancer.

Of more than 710,000 women, 2.4 percent ended up with breast cancer. And those in the top fifth of fiber intake were 11 percent less likely to do so than women in the bottom fifth.

That was after accounting for differences in risk factors like alcohol drinking, weight, hormone replacement therapy and family members with the disease.

Still, it’s impossible to rule out that big fiber eaters had healthier habits overall that would cut their risk, Jia-Yi Dong of Soochow University in Suzhou and his colleagues write in the American Journal of Clinical Nutrition.

And the potential effect was “very small,” Dr. Eleni Linos of Stanford University, who wasn’t involved in the research, told Reuters Health in an email.

About one in eight American women get breast cancer at some point, with less than a quarter of them dying from it.

Although the connection between breast cancer risk and fiber is a small one, fiber is “something that we know is healthy for you anyway,” said Christina Clarke, a research scientist at the Cancer Prevention Institute of California in Fremont.

Known benefits of a high-fiber diet include lower cholesterol and weight loss. If it turns out to cut cancer risk as well, that would be an extra bonus, Clarke said.

Fruits, vegetables, beans, and whole grains are all high in fiber.

According to the U.S. Department of Agriculture’s 2010 Dietary Guidelines, most Americans don’t get enough fiber. The guidelines recommend that women eat 25 grams of fiber per day and men eat 38 grams, while the average Americans gets just 15 grams a day.

“Increasing dietary fiber intake in the general public is of great public health significance,” the Chinese team concludes.

Source: http://www.reuters.com/article/2011/07/28/us-fiber-breast-cancer-idUSTRE76R6YM20110728

‘Super antibody’ fights off flu

The first antibody which can fight all types of the influenza A virus has been discovered, researchers claim.

Experiments on flu-infected mice, published in Science Express, showed the antibody could be used as an “emergency treatment”.

It is hoped the development will lead to a “universal vaccine” – currently a new jab has to be made for each winter as viruses change.

Virologists described the finding as a “good step forward”.

Many research groups around the world are trying to develop a universal vaccine. They need to attack something common to all influenza which does not change or mutate.

Human source

It has already been suggested that some people who had swine flu may develop ‘super immunity’ to other infections.

Scientists from the Medical Research Council’s National Institute for Medical Research at Mill Hill and colleagues in Switzerland looked at more than 100,000 samples of immune cells from patients who had flu or a flu vaccine.

They isolated an antibody – called FI6 – which targeted a protein found on the surface of all influenza A viruses called haemagglutinin.

Sir John Skehel, MRC scientist at Mill Hill, said: “We’ve tried every subtype of influenza A and it interacts with them all.

“We eventually hope it can be used as a therapy by injecting the antibody to stop the infection.”

Professor Antonio Lanzavecchia, director of the Institute for Research in Biomedicine, Switzerland, said: “As the first and only antibody which targets all known subtypes of the influenza A virus, FI6 represents an important new treatment option.”

When mice were given FI6, the antibody was “fully protective” against a later lethal doses of H1N1 virus.

Mice injected with the antibody up to two days after being given a lethal dose of the virus recovered and survived.

This is only the antibody, however, not the vaccine.

A vaccine would need to trigger the human body’s immune system to produce the antibody itself.

Sir John said the structure of the antibody and how it interacted with haemagglutinin had been worked out, which would help in the search for a vaccine, but that was “definitely years away”.

Professor John Oxford, a virologist at Queen Mary, University of London, said: “It’s pretty good if you’ve got one against the whole shebang, that’s a good step forward.”

Source: http://www.bbc.co.uk/news/health-14324901

Smelly socks tested in Tanzania as way to prevent malaria

In global public health, disease-fighting tools that are cheap, available and sustainable are the Holy Grail. It might be hard to top the one being tested in Tanzania as a way to prevent malaria: smelly socks.

Experiments in three villages where people get about 350 bites a year from malaria-infected mosquitoes are using dirty socks to lure the insects into traps, where they become contaminated with poisons and ultimately die.

Researchers hope that if the strategy works, it will eventually complement insecticide-treated bed nets as a low-tech way to prevent malaria, which kills nearly 900,000 people a year worldwide, most of them children.

“It’s a bold idea. Who would have thought there was a life-saving technology working in your laundry basket?” said Peter A. Singer, a physician who heads Grand Challenges Canada, a development agency of the Canadian government that is helping fund the research.

Previous lab studies have shown that smelly socks work well in attracting mosquitoes. Field experiments have shown that synthetic bait is more attractive than people, at least until the insects get close enough to realize there’s no blood waiting for them.

The new experiments, however, are the first head-to-head field tests of footwear vs. chemistry. The researchers hope the footwear wins.

“It is simply a cost issue and an expediency issue,” said Fredros O. Okumu, the Tanzanian entomologist leading the research. “Socks are more readily available, and you don’t have to mix any chemicals. It is the sort of thing that could be set up in a cottage factory.”

The traps are square boxes that look a little like commercial beehives. Some will contain the human-odor bait, which consists of simple chemicals (including lactic acid, ammonia and propionic acid) that are exuded by people, especially from the legs and feet. Some will contain socks worn for a day by adults. Others will contain cotton pads that schoolchildren will put inside their socks for a day and then deliver to researchers.

The researchers will compare the number of mosquitoes caught with each method.

Earlier work by Okumu and his colleagues at the Ifakara Health Institute in Tanzania showed that the chemical bait attracted four times as many mosquitoes as live people and that dirty socks worked just as well, at least in the lab. If the sock pads prove adequate, they will be the preferred bait.

The inside surfaces of some traps are coated with an organophosphate pesticide. Mosquitoes that land there will die within 24 hours. Other traps contain a fungus that infects the insects and kills them in five days — roughly half the time needed for the complicated cycle that enables a newly infected mosquito to transmit the malaria parasite to a person.

The bait-and-kill strategy is a new one in malaria prevention efforts.

Normally, attempts to prevent malaria by controlling mosquitoes, known as vector control, have aimed at driving the insects away from people or killing them once natural attraction has brought them into proximity.

Insecticide-treated bed nets, millions of which have been sold or given away in Africa in the past decade, have a long-acting repellant, permethrin. In many malaria-endemic areas, people spray the inside walls of dwellings with insecticide that kills mosquitoes when they land.

Bed nets have cut childhood deaths by about 20 percent in malaria-endemic areas. Modeling suggests that traps could reduce malaria transmission about as much as bed nets do in villages where half the households use them.

Despite its low-tech appearance, the strategy Okumu is testing is far more complicated, and potentially fraught with hazard, than it seems.

A key question is where to place traps. They need to be close enough to dwellings to attract mosquitoes, but not so close that they will increase people’s exposure to the disease-carrying insects. Okumu’s research suggests that the traps should be at least 100 feet from houses.

Another question is how many traps a village might need. Okumu has calculated the minimum number at 20 per 1,000 people, although in places where malaria transmission is especially intense and in certain village configurations, 130 traps per 1,000 people might be needed.

Despite these challenges, Singer said, projects such as these are what Grand Challenges Canada is looking to support. It is providing $388,000 for the research, and the Bill and Melinda Gates Foundation is providing a similar amount. The Gates Foundation gave Okumu $100,000 for preliminary studies, as well.

“We are inspired by people like Fredros,” Singer said. “We strongly believe that innovators in low-income countries are best situated to solve their own problems. He is an African researcher with an African innovation for an African problem.”

Okumu, who is a doctoral candidate at the London School of Hygiene and Tropical Medicine, said he is “working on the premise that this is a global problem — a global problem in a flat world.”

He said he doubted that there might be an application for his strategy — should it prove successful — in non-malarious places such as the United States. A pair of socks from a recent 10K run at the corner of a patio will only briefly divert mosquitoes. They’ll soon find the bare legs under the picnic table.

“Mosquitoes are still fairly clever animals,” he said. “What they are looking for is blood. They might be attracted to the socks, but they will not spend much time there.”

Source: http://www.washingtonpost.com/national/health-science/smelly-socks-tested-in-tanzania-as-way-to-prevent-malaria/2011/07/12/gIQAshifBI_story.html

Daily pill can prevent HIV infection

The partners of people who have HIV can protect themselves from infection by taking a once-daily pill, two groundbreaking studies in Botswana, Kenya and Uganda have shown.

The discovery could bring work to combat Aids close to a “tipping point”, experts say. Attempts to promote condom use to protect against HIV in the hardest-hit parts of the world, and particularly Africa, have hit cultural barriers and had limited success.

But now it appears that men or women who know – or suspect – their partner has HIV could protect themselves, secretly if necessary. The larger study, involving 4,758 “discordant” couples (where one has HIV but the other has not) in Kenya and Uganda, led by the University of Washington’s International Clinical Research Centre, shows that those taking a single daily tablet of the Aids drug tenofovir had 62% fewer infections and those who took a pill combining tenofovir and emtricitabine had 73% fewer infections than those who took a placebo pill.

The drugs have few side-effects, which is important if they are to be given to healthy individuals. Both are made by Gilead, which has licensed their manufacture to generic companies in the developing world, allowing them to produce cheap copies – so this is a relatively inexpensive intervention.

“This study demonstrates that antiretrovirals are a highly potent and fundamental cornerstone for HIV prevention and should become an integral part of global efforts for HIV prevention,” said Dr Connie Celum, professor of global health and medicine at the university and principal investigator of the study, known as the Partners PrEP Study, which was funded by the Bill and Melinda Gates Foundation.

The second study in Botswana was conducted by the United States Centres for Disease Control. It followed 1,200 heterosexual men and women without HIV who received either a once-daily tenofovir/emtricitabine tablet or a placebo pill. The antiretroviral tablet reduced the risk of acquiring HIV infection by roughly 63% overall.

“This is a major scientific breakthrough which re-confirms the essential role that antiretroviral medicine has to play in the Aids response,” said Michel Sidibé, Executive Director of the Joint United Nations Programme on HIV/Aids (UNAids). “These studies could help us to reach the tipping point in the HIV epidemic.”

The news follows hard on the heels of another very significant finding – that people with HIV who are taking combinations of antiretroviral drugs not only stay healthy themselves but are unlikely to infect their partner.

The two pieces of research give a massive boost to the cause of rolling out more Aids drugs and treating people at the earliest stage of their illness.

“Effective new HIV prevention tools are urgently needed, and these studies could have enormous impact in preventing heterosexual transmission,” said Dr Margaret Chan, WHO’s director general. “WHO will be working with countries to use the new findings to protect more men and women from HIV infection.”

Source: http://www.guardian.co.uk/world/2011/jul/14/hiv-daily-pill-breakthrough

Scientists Discover Gonorrhea Resistant to Antibiotics

(EndPlay Staff Reports) – A new untreatable strain of gonorrhea has been discovered in Japan and is causing concern in the United States.

Scientists reported that the strain, which is named H041, is resistant to all known forms of antibiotics. The researchers discussed the findings at a Monday meeting in Canada about three days after the CDC warned on July 8 that gonorrhea samples in the U.S. are also showing signs of drug resistance.

The concern is that the new strain of Neisseria gonorrhoeae is resistant to the cephalosporin family of antibiotics such as ceftriaxone, cefixime and cefpodoxime, which are widely used to treat the sexually transmitted disease in the United States. The CDC warned that this is a concern because it only leaves a few antibiotic options that are “simple, well-studied, and highly effective.”

The resistance to antibiotics, according to the CDC , was first documented in Asia before emerging in Hawaii and other western states then spreading elsewhere.

“This is a large public health problem and the era of untreatable gonorrhea may now have been initiated,” the team of researchers said at the Quebec City meeting of the International Society for Sexually Transmitted Disease Research, The Los Angeles Times reported.

The US Gonococcal Isolate Surveillance Project launched in 1986 has not discovered any U.S. cases in which treatment with cephalosporin antibiotics was a complete failure. The Times, though, reported there have been more cases that required unusually high doses of the antibiotic to cure them.

The majority of samples showing this trend were obtained from men having sex with men, the newspaper stated. The largest growth in cases noticed between 2000 and 2010 have been in Hawaii and California.

As a precaution, the CDC is suggesting dual treatment with another antibiotic such as azithromycin or doxycycline.

Gonorrhea, ABC News reported, is one of the most common STDs with about 700,000 new cases each year in the United States. It is spread through direct contact with the penis, vagina, mouth or anus and can also be transmitted from mother to baby during birth.

Only about half of infected women and less than five percent of infected men develop symptoms including a burning sensation and discharge. ABC News said it can spread to the skin, blood and other organs and cause pain, infertility and death if not treated.

Scientists are concerned that such a strain could spread quickly if new ways are not found to stop it. Dr. William Schaffner, chair of preventive medicine at Vanderbilt University Medical Center in Nashville, Tenn., told ABC News that this coincides with cutbacks in research as pharmaceutical companies invest less in the search for new antibiotics.

While the strain that did not respond at all to antibiotics was discovered in Kyoto, Japan, he warned, such bacteria “don’t need a passport” to spread.

Source: http://www.myfoxboston.com/dpps/health/scientists-discover-gonorrhea-resistant-to-antibiotics-dpgoha-20110712-fc_14088790

A deadly new reason to avoid deer ticks

Move over, Lyme disease: Another tick-borne illness is on the rise in various parts of the country, and this one can kill.

Known as babesiosis, the disease is caused by a microscopic parasite that attacks blood cells, causing flu-like symptoms that can make it difficult to accurately diagnose. Like Lyme disease, which is caused by bacteria, babesia microti parasites are carried by deer ticks.

First documented in Massachusetts in 1969, the once-obscure babesiosis has surfaced as a significant public health threat in parts of the Northeast and Upper Midwest over the last several years. A recent study in the journal Emerging Infectious Diseases, published by the U.S. Centers for Disease Control and Prevention, revealed that between 2001 and 2008 cases climbed from six to 119 in New York’s Lower Hudson Valley — a 20-fold regional increase.

And many cases may be escaping detection, experts say.

“I think it’s underreported. One of the reasons we’re seeing more about it is because people are becoming more aware,” said Dr. Peter Krause, a babesiosis researcher and senior research scientist at the Yale University School of Public Health. “The theory is that it’s spreading from east to west, as if you were dropping a pebble in a pond and it spread outward geographically.”

About 1,000 cases are reported annually in affected locales, Krause said, but many people with babesiosis have no symptoms and never know they’re harboring the parasite. For others, symptoms can include high fever, severe headache, fatigue, chills, and muscle aches and pains. It is treated with antimicrobial drugs, such as antibiotics.

People with compromised immune systems — including the elderly and those with cancer, HIV or no spleens — are especially at risk of potentially deadly complications such as organ failure. Between 10 percent and 20 percent of patients in those populations die as a result, Krause said.

The more prolific Lyme disease causes similar symptoms in early stage cases but is easier to diagnose by its telltale bullseye rash, said Dr. Barbara Herwaldt, a medical epidemiologist at the CDC who specializes in parasitic conditions.

Deer are pivotal to the life cycle of ticks carrying the babesia microti parasite by serving as a blood meal, shelter and a place to mate, Krause said. Ticks also feed on birds, who serve as carriers for Lyme disease, which affects the entire continental United States. Fortunately for humans, birds don’t carry babesia microti.

Krause noted that ticks need a moist climate to thrive, so dry states such as Arizona are not likely to see babesiosis cases caused by tick bites. But the disease can potentially spread to all states in an even sneakier way — through the blood supply.

Although a blood screening test is in trials, Krause said, donors are currently only asked if they have had babesiosis, and those who harbored it but never showed symptoms can pass it through their donated blood. And because most blood recipients are already physically compromised, babesiosis has about a 30 percent mortality rate in that group, he said.

“Getting babesiosis through the blood supply is a rare event and people shouldn’t panic,” he said. “I don’t think it will reach a crisis level, but it’s still a concern.”

To help prevent babesiosis, the CDC advises people with compromised immune systems or other vulnerabilities to avoid tick-infested wooded areas, particularly during warm months. The agency also recommends that everyone walk in the middle of trails and avoid bushy areas with lots of leaves or tall grasses and to use the repellent DEET and pre-treat clothes with an insect repellent containing permethrin before going outdoors.

The CDC also recommends doing full-body checks and showering within a few hours of being in the woods, as well as tossing used clothes in the dryer to kill any ticks that might be hiding there.

The authors of the study also advised clinicians to consider babesiosis in patients who have been exposed to ticks or received blood products and who show up for treatment with a fever and anemia resulting from the destruction of red blood cells.

Source: http://yourlife.usatoday.com/health/story/2011/07/A-deadly-new-reason-to-avoid-deer-ticks/49212700/1

Stem cell research and use in veterinary medicine

Stem cells show so much promise in human medicine. Cells that have the ability to become anything that the body needs is nothing short of a miracle. What is the role of stem cells in veterinary medicine? Do stem cells have a place? Many say they very much do.

Stem cells are able to be harvested from animals and are primarily used in horses, dogs, and cats for arthritic conditions.

There is much less controversy in veterinary medicine over the use of stem cells (at least at the present time) because of where they are harvested, or obtained. Rather than take stem cells from an umbilical cord or from an unborn fetus, the cells are harvested from the host itself.

How is this possible? Right now we know there is a certain amount of stem cells that exists in adult animals in either fat or bone marrow. These stem cells are considered adult stem cells and are somewhat limited in there ability to become “any cell” as compared to embryonic stem cells. However, adult stem cells can become cells similar to themselves.

What does this mean? There are individual reports of stem cells being used in veterinary medicine for conditions like ligament and tendon injuries in horses, as well as to treat a condition called laminitis. Everyone knows what tendons and ligaments are but what is laminitis?

Laminitis is a condition in horses that affects the blood supply and connective tissue from the bone to the hoof. In mild cases of laminitis there is just pain and inflammation which can be treated with rest, anti-inflammatories and special shoes to fit on the hoof.

Unfortunately, many times mild cases can progress to severe cases. There are also specific causes of laminitis that skip the mild phase and go right to the severe phase. The more severe phase can permanently damage the blood supply and the hoof would actually start to separate from the bone. If this happens many times it is irreversible and the only option for this is humane euthanasia. Stem cell therapy has been used to help to regrow the blood supply and connective tissue.

There are also reports that injecting adult stem cells harvested from bone marrow or fat can be used to treat arthritis in dogs and cats. There is a thin layer of cartilage that covers the bone at the joint called synovial cartilage. Synovial cartilage cushions the bone at the joint, as well as produces joint fluid. Joint fluid not only acts as a lubricant allowing the bones to slide back and forth, but also contains natural antioxidants and immune defenses.

When arthritis occurs in dogs the thin layers of synovial cartilage begin to degrade, or break down. It doesn’t happen all at once but when the cartilage is lost it does not grow back naturally. This is when you will hear orthopedists talk about “bone-on-bone” contact, and bone-on-bone contact is intensely painful.

The injection of stem cells into the joint has shown promise in regrowing this thin layer of synovial cartilage. No controlled studies have been performed to substantiate this claim. However, there are reports from various veterinarians using stem cells for this purpose that they see an improvement in their patients after receiving a stem cell treatment.

Using stem cells in veterinary patients to regrow tissue of any organ in the body is a long way off and even the use of stem cells for specific conditions like arthritis and laminitis has not been completely proven successful but there is hope on the horizon.

Source: http://www.northshoreoflongisland.com/Articles-i-2011-07-07-88828.112114-sub-Stem-cell-research-and-use-in-veterinary-medicine.html

Who wants to live forever? Scientist sees aging cured

(Reuters) – If Aubrey de Grey’s predictions are right, the first person who will live to see their 150th birthday has already been born. And the first person to live for 1,000 years could be less than 20 years younger.

A biomedical gerontologist and chief scientist of a foundation dedicated to longevity research, de Grey reckons that within his own lifetime doctors could have all the tools they need to “cure” aging — banishing diseases that come with it and extending life indefinitely.

“I’d say we have a 50/50 chance of bringing aging under what I’d call a decisive level of medical control within the next 25 years or so,” de Grey said in an interview before delivering a lecture at Britain’s Royal Institution academy of science.

“And what I mean by decisive is the same sort of medical control that we have over most infectious diseases today.”

De Grey sees a time when people will go to their doctors for regular “maintenance,” which by then will include gene therapies, stem cell therapies, immune stimulation and a range of other advanced medical techniques to keep them in good shape.

De Grey lives near Cambridge University where he won his doctorate in 2000 and is chief scientific officer of the non-profit California-based SENS (Strategies for Engineered Negligible Senescence) Foundation, which he co-founded in 2009.

He describes aging as the lifelong accumulation of various types of molecular and cellular damage throughout the body.

“The idea is to engage in what you might call preventative geriatrics, where you go in to periodically repair that molecular and cellular damage before it gets to the level of abundance that is pathogenic,” he explained.

CHALLENGE

Exactly how far and how fast life expectancy will increase in the future is a subject of some debate, but the trend is clear. An average of three months is being added to life expectancy every year at the moment and experts estimate there could be a million centenarians across the world by 2030.

To date, the world’s longest-living person on record lived to 122 and in Japan alone there were more than 44,000 centenarians in 2010.

Some researchers say, however, that the trend toward longer lifespan may falter due to an epidemic of obesity now spilling over from rich nations into the developing world.

De Grey’s ideas may seem far-fetched, but $20,000 offered in 2005 by the Massachusetts Institute of Technology (MIT) Technology Review journal for any molecular biologist who showed that de Grey’s SENS theory was “so wrong that it was unworthy of learned debate” was never won.

The judges on that panel were prompted into action by an angry put-down of de Grey from a group of nine leading scientists who dismissed his work as “pseudo science.”

They concluded that this label was not fair, arguing instead that SENS “exists in a middle ground of yet-to-be-tested ideas that some people may find intriguing but which others are free to doubt.”

CELL THERAPY

For some, the prospect of living for hundreds of years is not particularly attractive, either, as it conjures up an image of generations of sick, weak old people and societies increasingly less able to cope.

But de Grey says that’s not what he’s working for. Keeping the killer diseases of old age at bay is the primary focus.

“This is absolutely not a matter of keeping people alive in a bad state of health,” he told Reuters. “This is about preventing people from getting sick as a result of old age. The particular therapies that we are working on will only deliver long life as a side effect of delivering better health.”

De Grey divides the damage caused by aging into seven main categories for which repair techniques need to be developed if his prediction for continual maintenance is to come true.

He notes that while for some categories, the science is still in its earliest stages, there are others where it’s already almost there.

“Stem cell therapy is a big part of this. It’s designed to reverse one type of damage, namely the loss of cells when cells die and are not automatically replaced, and it’s already in clinical trials (in humans),” he said.

Stem cell therapies are currently being trialed in people with spinal cord injuries, and de Grey and others say they may one day be used to find ways to repair disease-damaged brains and hearts.

NO AGE LIMIT

Cardiovascular diseases are the world’s biggest age-related killers and de Grey says there is a long way to go on these though researchers have figured out the path to follow.

Heart diseases that cause heart failure, heart attacks and strokes are brought about by the accumulation of certain types of what de Grey calls “molecular garbage” — byproducts of the body’s metabolic processes — which our bodies are not able to break down or excrete.

“The garbage accumulates inside the cell, and eventually it gets in the way of the cell’s workings,” he said.

De Grey is working with colleagues in the United States to identify enzymes in other species that can break down the garbage and clean out the cells — and the aim then is to devise genetic therapies to give this capability to humans.

“If we could do that in the case of certain modified forms of cholesterol which accumulate in cells of the artery wall, then we simply would not get cardiovascular disease,” he said.

De Grey is reluctant to make firm predictions about how long people will be able to live in future, but he does say that with each major advance in longevity, scientists will buy more time to make yet more scientific progress.

In his view, this means that the first person who will live to 1,000 is likely to be born less than 20 years after the first person to reach 150.

“I call it longevity escape velocity — where we have a sufficiently comprehensive panel of therapies to enable us to push back the ill health of old age faster than time is passing. And that way, we buy ourselves enough time to develop more therapies further as time goes on,” he said.

“What we can actually predict in terms of how long people will live is absolutely nothing, because it will be determined by the risk of death from other causes like accidents,” he said.

“But there really shouldn’t be any limit imposed by how long ago you were born. The whole point of maintenance is that it works indefinitely.”

Source: http://www.reuters.com/article/2011/07/04/us-ageing-cure-idUSTRE7632ID20110704

New Drug Effectively Treats Hepatitis C

WEDNESDAY, June 22 (HealthDay News) — The recently approved drug Incivek, combined with two standard drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two new studies show.

Click here to find out more!

The drug works not only in patients just starting treatment, but in those who failed earlier treatment, the research found.

The hepatitis C virus can lurk in the body for years, causing liver damage, cirrhosis and even liver failure.

“This is a significant advance in the treatment of hepatitis C,” said Dr. David Bernstein, chief of the division of gastroenterology, hepatology and nutrition at North Shore University Hospital in Manhasset, N.Y., who was not involved in either study.

“We know that if we can get rid of the hepatitis C, we can prevent the progression of [liver] disease,” he said. “This means we can prevent the progression of cirrhosis, we can prevent the development of cancer and also prevent the need for liver transplantation in a large number of people.”

Incivek (telaprevir) was approved by the U.S. Food and Drug Administration in May and is the second drug in a class of drugs called protease inhibitors to be approved to fight hepatitis C. The other drug, called Victrelis (boceprevir), was also approved in May.

The standard treatment for hepatitis C has been a combination of two drugs, pegylated-interferon and ribavirin, which are given for a year. If protease inhibitors such as Incivek are added to the mix, the “viral cure” rate improves and the treatment time is reduced to six months, researchers found.

Both reports were published in the June 23 online edition of the New England Journal of Medicine.

In one study, a Phase 3 trial known as ADVANCE, patients were randomly assigned to either a placebo or the treatment in a double-blind study, which means that neither the patients nor the researchers know who’s getting the drug and who’s getting a sham treatment. This type of study is considered the gold standard for clinical research.

In the ADVANCE trial, 1,088 patients with hepatitis C who had never been treated for the condition were randomly assigned to standard therapy for 48 weeks, or telaprevir combined with standard therapy for eight or for 12 weeks, followed by standard therapy alone for a total treatment time of either 24 or 48 weeks.

The researchers found that 79 percent of those receiving Incivek for the longest period (24 weeks) had a “sustained response,” which basically means their hepatitis C was contained. Among those receiving standard care, 44 percent had a sustained response, the researchers noted.

“We have entered a new era of therapy for hepatitis C, which enables us to cure many more patients than we could before,” said lead researcher Dr. Ira M. Jacobson, from Weill Cornell Medical College in New York City.

Incivek needs to be given along with pegylated-interferon and ribavirin, Jacobson said. The researchers learned early on that Incivek alone reduces the level of the virus, but later the virus can become resistant to the drug, he said.

For the second study, called the REALIZE trial, 663 patients with hepatitis C who had failed standard therapy were divided into three groups. One group received Incivek plus standard therapy, another group was started on pegylated-interferon and ribavirin and then had Incivek added. The third group received standard therapy alone.

Here, the researchers found up to an 88 percent sustained response in patients receiving Incivek, compared with a 24 percent sustained response in the standard treatment group.

“These drugs represent a real milestone in the treatment of this disease,” said lead researcher Dr. Stefan Zeuzem, a professor of medicine at J.W. Goethe University Hospital in Frankfurt, Germany.

“There were very limited treatment options in the past, but now many patients have excellent chances to be cured, even if they already have advanced disease,” he said.

Bernstein noted that in the past, these patients could only be treated with more of the standard therapy for a longer period and the “cure” rate was only 10 percent. “Now you can treat these patients for six months with cure rates approaching 90 percent,” he said. “You are really offering hope to a large number of patients.”

The side effects of the medications include skin rashes, anemia, fatigue, itching, nausea, diarrhea, vomiting and taste changes. Some side effects were serious enough to cause a few participants to drop out, according to the study.

Incivek, made by Vertex Pharmaceuticals Inc., is sold to wholesalers for $49,200 for a four-week course of treatment, said Vertex spokeswomen Nikki Levy.

While both Incivek and Victrelis are important breakthroughs in the treatment of hepatitis C, new drugs with even fewer side effects and perhaps shorter treatment times are in clinical trials, Bernstein said.

Hepatitis C affects almost 4 million Americans, most of whom don’t know they’re infected. Often there are no symptoms, but it is the leading cause of liver transplantation in the United States and is linked to as many as 12,000 deaths a year, the researchers say.

Source: http://health.usnews.com/health-news/family-health/digestive-disorders/articles/2011/06/23/new-drug-effectively-treats-hepatitis-c?PageNr=1

Protein ‘helps predict Alzheimer’s risk’

A protein in spinal fluid could be used to predict the risk of developing Alzheimer’s disease, according to German researchers.

Patients with high levels of the chemical – soluble amyloid precursor protein beta – were more likely to develop the disease, they found.

Doctors said in the journal Neurology this was more precise than other tests.

Alzheimer’s Research UK said early diagnosis was a key goal, and the study represented a potential new lead.

Doctors analysed samples of spinal fluid from 58 patients with mild cognitive impairment, a memory-loss condition which can lead to Alzheimer’s.

The patients were followed for three years. Around a third developed Alzheimer’s.

Those who developed the illness had, on average, 1,200 nanograms/ml of the protein in the spinal fluid at the start of the study.

Those who did not started with just 932 nanograms/ml.

Beta amyloid proteins have already been implicated in Alzheimer’s itself, but not as a “predictor” of the disease.

The researchers said that a combination of soluble amyloid precursor protein beta, defective tau proteins, which are involved in the structure of brain cells, and a patient’s age was 80% accurate in predicting the onset of the disease.

Early diagnosis crucial

There is no cure for Alzheimer’s disease. If a treatment is developed, it is thought that it would need to be delivered early, before any permanent damage was done.

Dr Robert Perneczky, from the Technical University Munich, said: “Being able to identify who will develop Alzheimer’s disease very early in the process will be crucial in the future.

“Once we have treatments that could prevent Alzheimer’s disease, we could begin to treat very early and hopefully prevent the loss of memory and thinking skills that occurs with this devastating disease.”

More than 800,000 people have dementia in the UK, and that figure is expected to rise as populations get older.

Rebecca Wood, chief executive of Alzheimer’s Research UK, said: “The ability to diagnose Alzheimer’s early is a key goal for doctors and researchers. This small study provides a potential new lead to follow up.

“We will need to see larger trials before we can know how accurate this method could be as a diagnostic test. It will also be important to see how measurements of these proteins compare to those found in healthy people.”

Source: http://www.bbc.co.uk/news/health-13875984